Coffee Bioequivalence Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions
Liver FunctionsBioequivalenceCardiovascular RiskCardiometabolic Risk Markers
Interventions
DIETARY_SUPPLEMENT

Instant coffee given as a drink

Commercially available instant coffee (3.6 g) will be provided in the form of a drink prepared with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.

DIETARY_SUPPLEMENT

Coffee given in a tablet form

Commercially available instant coffee (3.6 g) will be provided as 4 tablets given with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.

DIETARY_SUPPLEMENT

Control (placebo)

A caffeine and coffee free control (3.6 g) will be provided as 4 tablets given with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.

Trial Locations (1)

RG6 6DZ

Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading, Reading

All Listed Sponsors
lead

University of Reading

OTHER